Short-term use of Infliximab in a case of recalcitrant idiopathic orbital inflammatory disease.
Osborne
Sarah F
SF
Sims
Jo L
JL
Rosser
Paul M
PM
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001379:Azathioprine / Q000008:administration & dosage; D001763:Blepharoptosis / Q000209:etiology; D004359:Drug Therapy, Combination; D005094:Exophthalmos / Q000209:etiology; D005123:Eye / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D008875:Middle Aged; D009886:Ophthalmoplegia / Q000209:etiology; D016727:Orbital Pseudotumor / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain / Q000209:etiology; D013960:Thyroid Function Tests; D013964:Thyroid Neoplasms / Q000209:etiology; D013997:Time Factors; D014792:Visual Acuity
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab; D001379:Azathioprine